⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
JBCHEPHARM - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.8
| Stock Code | JBCHEPHARM | Market Cap | 35,407 Cr. | Current Price | 2,204 ₹ | High / Low | 2,285 ₹ |
| Stock P/E | 51.0 | Book Value | 251 ₹ | Dividend Yield | 0.70 % | ROCE | 25.2 % |
| ROE | 18.7 % | Face Value | 1.00 ₹ | DMA 50 | 2,084 ₹ | DMA 200 | 1,919 ₹ |
| Chg in FII Hold | 1.45 % | Chg in DII Hold | -1.97 % | PAT Qtr | 116 Cr. | PAT Prev Qtr | 179 Cr. |
| RSI | 61.8 | MACD | 40.8 | Volume | 1,71,556 | Avg Vol 1Wk | 3,02,706 |
| Low price | 1,603 ₹ | High price | 2,285 ₹ | PEG Ratio | 2.36 | Debt to equity | 0.00 |
| 52w Index | 88.1 % | Qtr Profit Var | -22.6 % | EPS | 42.0 ₹ | Industry PE | 31.6 |
📈 Optimal Buy Price: 2,190 – 2,210 ₹
💰 Profit-Taking Levels: 2,240 ₹ / 2,265 ₹
🛑 Stop-Loss Zone: 2,170 ₹
⏳ Exit Guidance: If already holding, consider exiting near 2,240–2,250 ₹ if momentum slows. Exit below 2,170 ₹ if bearish volume spikes or RSI dips under 58.
✅ Positive
- Strong ROCE (25.2%) and ROE (18.7%) indicate efficient capital use.
- Price trading above DMA 50 (2,084 ₹) and DMA 200 (1,919 ₹), confirming bullish trend alignment.
- MACD at 40.8 shows strong bullish momentum.
- Debt-to-equity ratio at 0.00 reflects a debt-free balance sheet.
- FII holding increased (+1.45%), showing foreign investor confidence.
⚠️ Limitation
- High P/E (51.0) vs industry PE (31.6) suggests overvaluation.
- PEG ratio at 2.36 indicates expensive valuation relative to growth.
- Volume (1.71 lakh) below weekly average (3.02 lakh), limiting intraday volatility.
- Dividend yield at 0.70% is modest.
📉 Company Negative News
- Quarterly PAT declined (₹179 Cr → ₹116 Cr), showing earnings pressure.
- DII holding decreased (-1.97%), reflecting reduced domestic institutional support.
📊 Company Positive News
- Strong 52-week index performance at 88.1% highlights price strength.
- EPS at 42.0 ₹ reflects solid earnings power.
🏭 Industry
- Industry PE at 31.6 vs JBCHEPHARM’s 51.0, suggesting premium valuation.
- Pharma sector remains resilient with long-term demand drivers.
📌 Conclusion
JBCHEPHARM shows strong technical momentum and fundamentals but trades at a premium valuation. Suitable for cautious intraday trades with entry near 2,190–2,210 ₹, profit exits around 2,240–2,265 ₹, and strict stop-loss at 2,170 ₹. Reduced volume and high P/E warrant disciplined risk management.
Would you like me to extend this into a peer benchmarking against other pharma stocks, or prepare a swing trade analysis for medium-term positioning?